

Fulfords India to maintain hepatitis injection production

07 March 2018 | News | By Manbeena Chawla

Fulfords India has also been asked to submit a weekly report along with production plan for the next week to National Pharmaceutical Pricing Authority (NPPA) and DOP.



Department of Pharmaceuticals (DOP) has invoked powers under the Drugs Prices Control Order, 2013 to direct Fulfords India to maintain production, distribution and availability of Viraferonpeg 100 mcg injection in the market. The injection is used for treatment of chronic hepatitis C.

The company is directed to continue to maintain the same level of production and availability as during the period from November 2013 to November 2015 of the Viraferonpeg 100 mcg injection.

Fulfords India has also been asked to submit a weekly report along with production plan for the next week to National Pharmaceutical Pricing Authority (NPPA) and DOP.